Physician profile
Karol Rosner
NPI 1053425884
$1,263.03
in general payments reported to CMS, 2019-2025
18 companies · $550 in 2025
The $550 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2021: $57.77 · 2022: $60.46 · 2024: $439 · 2025: $550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.02 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $163.88 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $158.05 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $137.10 | 2024 | |
| Novartis Pharmaceuticals Corporation | $121.34 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.42 | 2021-2025 | |
| Vifor Pharma, INC. | $83.18 | 2024-2025 | Veltassa |
| Biotronik INC. | $82.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $76.49 | 2019-2025 | Jynarque, Rexulti |
| Fresenius USA Marketing, INC. | $61.83 | 2019-2024 | |
| Scpharmaceuticals INC. | $52.64 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $50.64 | 2019-2022 | |
| Biomerieux INC | $32.60 | 2024 | Vidas Nephrocheck |
| Ardelyx, INC. | $30.50 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $24.67 | 2025 | Empaveli |
| Akebia Therapeutics INC | $21.89 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.12 | 2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.87 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $15.64 | 2024 | Benlysta, Jesduvroq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Rosner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.